- Immutep Limited (NASDAQ:IMMP) announced new data in 1st line non-small cell lung cancer from the INSIGHT-003 Phase I trial evaluating eftilagimod alpha in conjunction with standard-of-care anti-PD-1 therapy and doublet chemotherapy (carboplatin/pemetrexed).
- The triple combination therapy remains well-tolerated and continues to show favorable initial efficacy signals, attaining a 67% overall response rate (ORR) and 91% disease control rate (DCR) in advanced or metastatic non-squamous 1st line non-small cell lung cancer patients (N=21).
- Related: Immutep Shares Spike As Cancer Treatment Shows Favorable Results In Phase 2 Trial.
- The 67% ORR regardless of PD-L1 expression, and 65% response rate in patients with PD-L1 TPS <50% for the triple combination compare favorably to reported results from a registrational trial of anti-PD-1 and doublet chemotherapy in the same patient population that yielded an ORR of 48% regardless of PD-L1 expression and a response rate of 40.8% in patients with PD-L1 TPS <50%.
- The INSIGHT-003 trial was recently expanded to enroll 50 patients based on the favorable safety and efficacy results, and additional data is expected to be presented at a major medical conference in H2 CY2023.
- Price Action: IMMP shares are up 10.8% at $2.5489 on the last check Wednesday.
BlackBerry QNX Announces General Availability Of QNX SDP 8.0, Its Foundation For Next Generation Automotive And IoT Systems
Features fifth-generation architecture with state-of-the-art safe and secure microkernel, advanced tooling and cloud enablement to future-proof mission-critical embedded system design LAS VEGAS, Jan. 8, 2024
